Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Harmony Biosciences (HRMY) stock in plain English

Free brief · no signupStart here
HRMYPublished Nov 19, 2026
Harmony Biosciences Holdings Inc
Healthcare · Biotechnology
Commercializes prescription pharmaceuticals designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.
Assets:
Wakix product lineHistamine 3 receptor antagonist approved for narcolepsy
Pitolisant clinical pipelineOngoing clinical trials for idiopathic hypersomnia and genetic sleep conditions
Pennsylvania headquartersCorporate office and administrative hub in Plymouth Meeting
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

91
OPS ScoreOperating finances
Latest quote
-0.39%$32.98
$1.94B
10.9×
$988.11M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was HRMY. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Harmony Biosciences (HRMY) do?

Harmony Biosciences Holdings Inc (HRMY) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Commercializes prescription pharmaceuticals designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. Sells an approved therapy for rare sleep disorders using exclusive North American licensing rights. It is worth $1.94B on the market and sold $988.11M over the last year.

Market cap
$1.94B
P/E ratio
10.9×
Annual sales
$988.11M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 19, 2026

Brands and businesses behind HRMY

  • Wakix: This prescription pill earns revenue from narcolepsy patients seeking treatment for excessive daytime sleepiness and sudden muscle weakness.

HRMY’s flags, in plain English

Each flag is a number from Harmony Biosciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Wide Gross Margin

Gross margin of 71.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 40.3% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Growth vs Price

The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.

Heavily Shorted

13.2% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about HRMY

How big is Harmony Biosciences?

Harmony Biosciences’ market cap is $1.94B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $988.11M: what customers paid the company over the last year, before any costs.

What is HRMY’s P/E ratio?

HRMY’s P/E ratio is 10.9×. Investors pay about 10.9 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with HRMY?

The company generates almost all of its revenue from a single commercial product, Wakix. That is one risk on Harmony Biosciences’ card. Its first risk flag is Heavily Shorted, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Harmony Biosciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. HRMY’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card